The discontinuation rate for pembrolizumab due to side effects was lower in the LITESPARK 022 trial compared to the earlier Keynote 564 trial (20%). This trend suggests that as clinicians gain more experience with immune checkpoint inhibitors, they are becoming more adept at managing immune-related adverse events, allowing more patients to complete their therapy.
Even when trials like LITESPARK 022 and Keynote 564 use identical eligibility criteria, outdated staging systems result in patient populations with different underlying risks. This makes direct comparison of outcomes between trials, even for the same drug, an unfair and statistically flawed analysis that ignores the function of a control arm.
The common belief that belzutifan has a delayed onset of action, based on prior studies, is challenged. The late curve separation in earlier trials was likely a statistical artifact from early, unverified patient censoring, not a true biological mechanism. The LITESPARK 022 trial showed early separation, suggesting the drug works sooner than thought.
In the adjuvant (post-surgery) setting, Disease-Free Survival (DFS) is a more crucial and patient-relevant endpoint than Progression-Free Survival (PFS) is in the metastatic setting. A DFS event signifies the cancer's return, a major psychological and clinical blow, distinct from the growth of an already-known tumor in the metastatic context.
Despite initial preclinical concerns that HIF-2 inhibition might dampen immune response, the success of the Pembro+Belzutifan combination is likely due to the simple additive effect of two active drugs. Newer data refutes the immune-dampening theory, showing no negative impact on the tumor microenvironment and possibly even a reduction in immunosuppressive cells.
The next major advance in adjuvant kidney cancer will be a biomarker to select who needs treatment. The key is developing a Minimal Residual Disease (MRD) test based on the epigenome (e.g., chromatin modifications) rather than just ctDNA mutations. This is because the critical biological signals in RCC are found in epigenetic regulation, not just the genome.
Previous adjuvant trials in kidney cancer using more toxic VEGF-TKIs largely failed. Belzutifan's success suggests that in the adjuvant setting, a drug's tolerability and the ability for patients to maintain dose intensity are more critical for efficacy than raw potency in advanced disease. TKIs were often too toxic for patients to endure for a full year.